SQ-LIP-000005 · v1.0 (archived) · View current version →
Does lipedema increase the prevalence of joint hypermobility?
Probably, but the evidence is mostly observational. A cross-sectional cohort reported joint hypermobility in about 44% of adult lipedema patients. No randomized or longitudinal evidence establishes a causal link, and diagnostic criteria for both lipedema and hypermobility are heterogeneous across studies.
Knowledge freshness = share of the 1 indexed evidence sources from the last 5 years (newest 2025, oldest 2025) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
supporting contradicting refining / context Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
What changed in this version
Initial version (v1.0): 1 founding claims indexed from the lipedema pilot. The automated surveillance loop (new-article ingestion → supports / contradicts / refines) has not yet run.
Supporting claims
- SCR-LIP-000017 supporting
Joint hypermobility (Hypermobility Spectrum Disorder) is a frequent comorbidity of lipedema, present in approximately 44% of adult patients in a cross-sectional cohort.
DOI:10.3390/jcm14207195
Contradictory claims
- None indexed yet.
Major uncertainty
Hypermobility cutoffs and lipedema definitions vary across studies; single cross-sectional design.
Version history
- SQ-LIP-000005 · v1.0 — 2026-05-30 — founding index (1 claims) · view this version